Ketamine for Chronic Fatigue Syndrome (CFS/ME)

Understanding Chronic Fatigue Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, debilitating condition characterized by profound fatigue that is not improved by rest, worsened by physical or cognitive exertion (post-exertional malaise), and accompanied by a range of neurological, immunological, and autonomic symptoms. An estimated 1 to 2.5 million Americans live with ME/CFS, with the condition disproportionately affecting women.

ME/CFS has no FDA-approved pharmacological treatment. Current management relies on symptom-targeted therapies, activity pacing, and supportive care. The lack of effective treatments has driven interest in novel therapeutic approaches, including ketamine — a drug whose mechanisms of action overlap with several pathological features of ME/CFS.

Why Ketamine Is Being Investigated for ME/CFS

Neuroinflammation

A growing body of evidence implicates neuroinflammation in the pathophysiology of ME/CFS. Positron emission tomography (PET) studies have demonstrated widespread microglial activation in the brains of ME/CFS patients, particularly in regions involved in cognitive processing, pain modulation, and autonomic regulation. Elevated levels of pro-inflammatory cytokines — including interleukin-6 (IL-6), interleukin-1 beta (IL-1B), and tumor necrosis factor-alpha (TNF-alpha) — have been reported in blood and cerebrospinal fluid.

Ketamine has documented anti-inflammatory properties, including suppression of pro-inflammatory cytokine production and modulation of microglial activation. These properties provide a mechanistic rationale for its potential use in ME/CFS, where neuroinflammation may drive key symptoms including cognitive dysfunction ("brain fog"), pain, and fatigue.

NMDA Receptor Dysregulation

The NMDA receptor system, ketamine's primary pharmacological target, may be dysregulated in ME/CFS. Some researchers have proposed that excessive glutamatergic signaling and excitotoxicity contribute to the neuronal dysfunction observed in the condition. Elevated glutamate levels have been found in certain brain regions of ME/CFS patients using magnetic resonance spectroscopy.

By blocking NMDA receptors, ketamine could theoretically reduce excitotoxic signaling and restore a healthier balance between excitatory and inhibitory neurotransmission — a mechanism detailed in our overview of how ketamine works in the brain.

Central Sensitization

ME/CFS shares significant clinical and mechanistic overlap with other central sensitization syndromes, including fibromyalgia and chronic pain conditions. Central sensitization involves heightened sensitivity of the central nervous system to sensory input, leading to amplified pain, fatigue, and cognitive symptoms. Ketamine's ability to interrupt central sensitization through NMDA receptor blockade is well-documented in pain medicine and provides another rationale for investigation in ME/CFS.

Neuroplasticity Deficits

Patients with ME/CFS often exhibit cognitive impairment, including difficulties with memory, attention, and information processing. These deficits may reflect impaired neuroplasticity — the brain's ability to form and reorganize synaptic connections. Ketamine promotes rapid synaptogenesis through BDNF release and activation of the mTOR pathway, potentially restoring synaptic function in circuits affected by the disease.

Clinical Evidence

Current State of Research

As of early 2026, the clinical evidence for ketamine in ME/CFS is limited and consists primarily of case reports, small open-label studies, and anecdotal clinical observations. No large randomized controlled trials have been completed specifically for ME/CFS, and ketamine is not an established treatment for this condition.

Pain and Cognitive Outcomes

The most relevant clinical data comes from studies of ketamine for conditions that overlap with ME/CFS:

• Fibromyalgia: Several controlled trials have demonstrated that ketamine infusions reduce pain and improve function in fibromyalgia patients. Given the high comorbidity between fibromyalgia and ME/CFS (some researchers consider them part of the same spectrum), these findings have indirect relevance.
• Neuropathic pain with fatigue: Studies of ketamine for chronic pain have occasionally reported improvements in fatigue and cognitive function as secondary outcomes, though these were not primary endpoints.
• Treatment-resistant depression with fatigue: ME/CFS frequently co-occurs with depression, and ketamine's demonstrated efficacy in treatment-resistant depression may benefit ME/CFS patients with comorbid mood disorders.

Case Reports

Published case reports have described individual ME/CFS patients who experienced meaningful improvements in fatigue severity, cognitive function, and pain following ketamine infusions. While case reports cannot establish causation, they provide preliminary signals that warrant further investigation. Some patients reported improvements lasting days to weeks after a single infusion, consistent with ketamine's known duration of effect in psychiatric applications.

Potential Mechanisms of Benefit

Resetting Glial Cell Activation

One hypothesis for how ketamine might benefit ME/CFS patients involves the "resetting" of chronically activated glial cells. If sustained microglial and astrocyte activation contributes to a self-perpetuating neuroinflammatory state in ME/CFS, ketamine's ability to modulate glial signaling could potentially interrupt this cycle.

Autonomic Nervous System Effects

ME/CFS is commonly associated with autonomic dysfunction, including orthostatic intolerance and abnormal heart rate variability. Ketamine has complex effects on the autonomic nervous system, including sympathomimetic properties that increase heart rate and blood pressure. These effects require careful monitoring in ME/CFS patients, who may be particularly sensitive to autonomic perturbation.

Mitochondrial Function

Emerging research suggests that mitochondrial dysfunction may underlie the energy production deficits in ME/CFS. While ketamine's effects on mitochondrial function are not fully characterized, some preclinical data indicate that sub-anesthetic ketamine may influence mitochondrial membrane potential and bioenergetics. This area requires considerably more research before clinical conclusions can be drawn.

Important Limitations and Cautions

No Established Protocol

There is no evidence-based dosing protocol for ketamine in ME/CFS. The sub-anesthetic doses used for depression (typically 0.5 mg/kg IV over 40 minutes) serve as a starting reference point, but optimal dosing for ME/CFS may differ, and the risk-benefit ratio has not been established.

Post-Exertional Malaise Risk

ME/CFS patients are highly susceptible to symptom exacerbation following any physiological stressor — a hallmark feature called post-exertional malaise (PEM). Ketamine infusions represent a physiological perturbation that could theoretically trigger PEM in susceptible individuals. Clinicians considering ketamine for ME/CFS patients should be aware of this risk and monitor for delayed symptom worsening.

Autonomic Sensitivity

Many ME/CFS patients have significant autonomic instability. Ketamine's sympathomimetic effects — increased heart rate, elevated blood pressure — may be poorly tolerated in patients with orthostatic intolerance, postural orthostatic tachycardia syndrome (POTS), or other dysautonomic features.

Off-Label Use

Any use of ketamine for ME/CFS is entirely off-label and based on limited evidence. Patients considering this option should have a thorough discussion with their provider about the experimental nature of the treatment, the lack of established efficacy, and the potential risks. For guidance on evaluating providers, see how to find a ketamine provider.

Future Directions

Several research priorities could advance understanding of ketamine's potential role in ME/CFS:

• Randomized controlled trials specifically enrolling ME/CFS patients, with fatigue severity and cognitive function as primary outcomes
• Biomarker-guided studies that stratify patients by neuroinflammatory markers, glutamate levels, or other measurable features to identify subgroups most likely to respond
• Neuroimaging studies examining whether ketamine alters patterns of microglial activation or brain connectivity in ME/CFS
• Comparison with other NMDA modulators that may share ketamine's beneficial mechanisms without its dissociative effects
• Long-term safety data specific to ME/CFS patients, who may require different monitoring due to their unique physiological vulnerabilities

Summary

Ketamine is not an established treatment for ME/CFS, but its pharmacological profile — anti-inflammatory effects, NMDA receptor antagonism, neuroplasticity enhancement, and anti-central-sensitization properties — aligns with several proposed disease mechanisms. Current evidence is preliminary and insufficient to recommend routine use. However, the mechanistic rationale is strong enough to justify formal clinical investigation, and ongoing research may clarify whether ketamine has a role to play in managing this challenging condition.

References

• Neuroinflammation in ME/CFS — National Institutes of Health (NIH) — NIH ME/CFS research initiative and overview
• Nakatomi Y, et al. Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-PK11195-PET Study. Journal of Nuclear Medicine, 2014 — PET evidence of widespread neuroinflammation in ME/CFS
• Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press, 2015 — Comprehensive IOM report establishing diagnostic criteria
• Ketamine's Anti-Inflammatory Properties — Mayo Clinic Proceedings — Context on ketamine's anti-inflammatory mechanisms
• Morris G, Maes M. A neuro-immune model of myalgic encephalomyelitis/chronic fatigue syndrome. Metabolic Brain Disease, 2013 — Neuro-immune framework for understanding ME/CFS pathophysiology